Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L12 pseudogene 22 (RPL12P22) is a **pseudogene** found in the human genome. It is named due to its sequence similarity to the functional ribosomal protein L12 gene (RPL12), which encodes a protein component of the 60S ribosomal subunit involved in catalyzing protein synthesis. However, as a pseudogene, RPL12P22 does not produce a functional protein and is not considered a therapeutic target or involved in known biological functions or disease associations. Pseudogenes like RPL12P22 are typically noncoding remnants of once-functional genes that have lost their protein-coding potential due to mutations and other genomic changes[1][2][4][8]. RPL12 is a functional gene coding for a ribosomal protein involved in protein synthesis, but RPL12P22 is only a *genomic relic* and not actively translated or functionally relevant as a therapeutic target[3][5]. No information is available regarding drug interactions, disease links, or biomarker relevance for RPL12P22, because pseudogenes do not produce functional gene products[1][2][4][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L12 pseudogene 22 (RPL12P22).